ID   IMDH2_HUMAN             Reviewed;         514 AA.
AC   P12268; Q6LEF3;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1991, sequence version 2.
DT   12-APR-2017, entry version 204.
DE   RecName: Full=Inosine-5'-monophosphate dehydrogenase 2 {ECO:0000255|HAMAP-Rule:MF_03156};
DE            Short=IMP dehydrogenase 2 {ECO:0000255|HAMAP-Rule:MF_03156};
DE            Short=IMPD 2 {ECO:0000255|HAMAP-Rule:MF_03156};
DE            Short=IMPDH 2 {ECO:0000255|HAMAP-Rule:MF_03156};
DE            EC=1.1.1.205 {ECO:0000255|HAMAP-Rule:MF_03156};
DE   AltName: Full=IMPDH-II;
GN   Name=IMPDH2 {ECO:0000255|HAMAP-Rule:MF_03156}; Synonyms=IMPD2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PARTIAL PROTEIN SEQUENCE.
RX   PubMed=2902093;
RA   Collart F.R., Huberman E.;
RT   "Cloning and sequence analysis of the human and Chinese hamster
RT   inosine-5'-monophosphate dehydrogenase cDNAs.";
RL   J. Biol. Chem. 263:15769-15772(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Spleen;
RX   PubMed=1969416;
RA   Natsumeda Y., Ohno S., Kawasaki H., Konno Y., Weber G., Suzuki K.;
RT   "Two distinct cDNAs for human IMP dehydrogenase.";
RL   J. Biol. Chem. 265:5292-5295(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Blood;
RX   PubMed=7999076; DOI=10.1006/bbrc.1994.2698;
RA   Glesne D.A., Huberman E.;
RT   "Cloning and sequence of the human type II IMP dehydrogenase gene.";
RL   Biochem. Biophys. Res. Commun. 205:537-544(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7896827; DOI=10.1074/jbc.270.12.6808;
RA   Zimmermann A.G., Spychala J., Mitchell B.S.;
RT   "Characterization of the human inosine-5'-monophosphate dehydrogenase
RT   type II gene.";
RL   J. Biol. Chem. 270:6808-6814(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=B-cell, Colon, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 461-514.
RX   PubMed=8098009; DOI=10.1006/geno.1993.1177;
RA   Glesne D.A., Collart F.R., Varkony T., Drabkin H., Huberman E.;
RT   "Chromosomal localization and structure of the human type II IMP
RT   dehydrogenase gene.";
RL   Genomics 16:274-277(1993).
RN   [7]
RP   PROTEIN SEQUENCE OF 2-11, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, AND
RP   ENZYME REGULATION.
RX   PubMed=7903306;
RA   Carr S.F., Papp E., Wu J.C., Natsumeda Y.;
RT   "Characterization of human type I and type II IMP dehydrogenases.";
RL   J. Biol. Chem. 268:27286-27290(1993).
RN   [8]
RP   PROTEIN SEQUENCE OF N-TERMINUS, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=7763314; DOI=10.1016/0006-2952(95)00026-V;
RA   Hager P.W., Collart F.R., Huberman E., Mitchell B.S.;
RT   "Recombinant human inosine monophosphate dehydrogenase type I and type
RT   II proteins. Purification and characterization of inhibitor binding.";
RL   Biochem. Pharmacol. 49:1323-1329(1995).
RN   [9]
RP   SUBCELLULAR LOCATION, AND NUCLEIC ACID-BINDING.
RX   PubMed=14766016; DOI=10.1042/BJ20031585;
RA   McLean J.E., Hamaguchi N., Belenky P., Mortimer S.E., Stanton M.,
RA   Hedstrom L.;
RT   "Inosine 5'-monophosphate dehydrogenase binds nucleic acids in vitro
RT   and in vivo.";
RL   Biochem. J. 379:243-251(2004).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-400, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [12]
RP   POLYMORPHISM, AND VARIANT PHE-263.
RX   PubMed=17496727; DOI=10.1097/FPC.0b013e328012b8cf;
RA   Wang J., Zeevi A., Webber S., Girnita D.M., Addonizio L., Selby R.,
RA   Hutchinson I.V., Burckart G.J.;
RT   "A novel variant L263F in human inosine 5'-monophosphate dehydrogenase
RT   2 is associated with diminished enzyme activity.";
RL   Pharmacogenet. Genomics 17:283-290(2007).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-122, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-511, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-122 AND SER-416, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-122; SER-160 AND
RP   SER-416, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-416, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS), AND ACTIVE SITE.
RX   PubMed=10097070; DOI=10.1073/pnas.96.7.3531;
RA   Colby T.D., Vanderveen K., Strickler M.D., Markham G.D.,
RA   Goldstein B.M.;
RT   "Crystal structure of human type II inosine monophosphate
RT   dehydrogenase: implications for ligand binding and drug design.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:3531-3536(1999).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) IN COMPLEX WITH INHIBITOR AND
RP   POTASSIUM.
RA   Risal D., Strickler M.D., Goldstein B.M.;
RT   "Crystal structure of human inosine monophosphate dehydrogenase type
RT   II complexed with the MPA/NAD analog C2-MAD.";
RL   Submitted (DEC-2002) to the PDB data bank.
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) IN COMPLEX WITH NAD(+).
RA   Risal D., Strickler M.D., Goldstein B.M.;
RT   "The conformation of NAD bound to human inosine monophosphate
RT   Dehydrogenase Type II.";
RL   Submitted (DEC-2002) to the PDB data bank.
CC   -!- FUNCTION: Catalyzes the conversion of inosine 5'-phosphate (IMP)
CC       to xanthosine 5'-phosphate (XMP), the first committed and rate-
CC       limiting step in the de novo synthesis of guanine nucleotides, and
CC       therefore plays an important role in the regulation of cell
CC       growth. Could also have a single-stranded nucleic acid-binding
CC       activity and could play a role in RNA and/or DNA metabolism. It
CC       may also have a role in the development of malignancy and the
CC       growth progression of some tumors.
CC   -!- CATALYTIC ACTIVITY: Inosine 5'-phosphate + NAD(+) + H(2)O =
CC       xanthosine 5'-phosphate + NADH. {ECO:0000255|HAMAP-Rule:MF_03156}.
CC   -!- COFACTOR:
CC       Name=K(+); Xref=ChEBI:CHEBI:29103;
CC   -!- ENZYME REGULATION: Mycophenolic acid (MPA) is a non-competitive
CC       inhibitor that prevents formation of the closed enzyme
CC       conformation by binding to the same site as the amobile flap. In
CC       contrast, mizoribine monophosphate (MZP) is a competitive
CC       inhibitor that induces the closed conformation. MPA is a potent
CC       inhibitor of mammalian IMPDHs but a poor inhibitor of the
CC       bacterial enzymes. MZP is a more potent inhibitor of bacterial
CC       IMPDH. Subject to product inhibition by XMP and NADH. Also
CC       inhibited by ADP. {ECO:0000255|HAMAP-Rule:MF_03156,
CC       ECO:0000269|PubMed:7903306}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=9.3 uM for Inosine 5'-phosphate {ECO:0000269|PubMed:7763314,
CC         ECO:0000269|PubMed:7903306};
CC         KM=32 uM for NAD(+) {ECO:0000269|PubMed:7763314,
CC         ECO:0000269|PubMed:7903306};
CC   -!- PATHWAY: Purine metabolism; XMP biosynthesis via de novo pathway;
CC       XMP from IMP: step 1/1. {ECO:0000255|HAMAP-Rule:MF_03156}.
CC   -!- SUBUNIT: Homotetramer. {ECO:0000255|HAMAP-Rule:MF_03156,
CC       ECO:0000269|PubMed:7903306, ECO:0000269|Ref.22,
CC       ECO:0000269|Ref.23}.
CC   -!- INTERACTION:
CC       Q96GX9:APIP; NbExp=3; IntAct=EBI-353389, EBI-359248;
CC       Q9BU20:RSG1; NbExp=5; IntAct=EBI-353389, EBI-750332;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000255|HAMAP-Rule:MF_03156,
CC       ECO:0000269|PubMed:14766016}. Nucleus {ECO:0000255|HAMAP-
CC       Rule:MF_03156, ECO:0000269|PubMed:14766016}.
CC   -!- TISSUE SPECIFICITY: IMP type I is the main species in normal
CC       leukocytes and type II predominates over type I in the tumor.
CC   -!- INDUCTION: Selectively up-regulated in neoplastic and replicating
CC       cells.
CC   -!- PTM: The N-terminus is blocked.
CC   -!- POLYMORPHISM: Genetic variants in the IMPDH2 gene may account for
CC       the large inter-individual variability in enzyme activity,
CC       immunosuppressive efficacy and side effects in transplant
CC       recipients receiving mycophenolic acid.
CC   -!- MISCELLANEOUS: Because IMPDH activity is tightly linked with cell
CC       proliferation, it has been recognized as a target for cancer and
CC       viral chemotherapy and as a target for immunosuppressive drugs.
CC       The activities of the antitumor drug tiazofurin, the antiviral
CC       drug ribavirin, and the immunosuppressive drugs mizoribine and
CC       mycophenolic acid (MPA) are attributed to the inhibition of IMPDH.
CC       In addition, bacterial and parasitic IMPDH's differ significantly
CC       from mammalian enzymes, which makes it a suitable target for anti-
CC       infective drugs.
CC   -!- SIMILARITY: Belongs to the IMPDH/GMPR family. {ECO:0000255|HAMAP-
CC       Rule:MF_03156}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J04208; AAA36112.1; -; mRNA.
DR   EMBL; L33842; AAA67054.1; -; Genomic_DNA.
DR   EMBL; L39210; AAB70699.1; -; Genomic_DNA.
DR   EMBL; BC006124; AAH06124.1; -; mRNA.
DR   EMBL; BC012840; AAH12840.1; -; mRNA.
DR   EMBL; BC015567; AAH15567.1; -; mRNA.
DR   EMBL; L08114; AAA36113.1; -; Genomic_DNA.
DR   CCDS; CCDS2786.1; -.
DR   PIR; I52303; A31997.
DR   RefSeq; NP_000875.2; NM_000884.2.
DR   UniGene; Hs.654400; -.
DR   PDB; 1B3O; X-ray; 2.90 A; A/B=1-514.
DR   PDB; 1NF7; X-ray; 2.65 A; A/B=1-514.
DR   PDB; 1NFB; X-ray; 2.90 A; A/B=1-514.
DR   PDBsum; 1B3O; -.
DR   PDBsum; 1NF7; -.
DR   PDBsum; 1NFB; -.
DR   ProteinModelPortal; P12268; -.
DR   SMR; P12268; -.
DR   BioGrid; 109828; 89.
DR   IntAct; P12268; 34.
DR   MINT; MINT-2860057; -.
DR   STRING; 9606.ENSP00000321584; -.
DR   BindingDB; P12268; -.
DR   ChEMBL; CHEMBL2002; -.
DR   DrugBank; DB04566; Inosinic Acid.
DR   DrugBank; DB01033; Mercaptopurine.
DR   DrugBank; DB00688; Mycophenolate mofetil.
DR   DrugBank; DB01024; Mycophenolic acid.
DR   DrugBank; DB00157; NADH.
DR   DrugBank; DB00811; Ribavirin.
DR   DrugBank; DB03070; Selenazole-4-Carboxyamide-Adenine Dinucleotide.
DR   DrugBank; DB06103; VX-148.
DR   GuidetoPHARMACOLOGY; 2625; -.
DR   iPTMnet; P12268; -.
DR   PhosphoSitePlus; P12268; -.
DR   SwissPalm; P12268; -.
DR   BioMuta; IMPDH2; -.
DR   DMDM; 124419; -.
DR   REPRODUCTION-2DPAGE; IPI00291510; -.
DR   REPRODUCTION-2DPAGE; P12268; -.
DR   UCD-2DPAGE; P12268; -.
DR   EPD; P12268; -.
DR   MaxQB; P12268; -.
DR   PaxDb; P12268; -.
DR   PeptideAtlas; P12268; -.
DR   PRIDE; P12268; -.
DR   TopDownProteomics; P12268; -.
DR   DNASU; 3615; -.
DR   Ensembl; ENST00000326739; ENSP00000321584; ENSG00000178035.
DR   GeneID; 3615; -.
DR   KEGG; hsa:3615; -.
DR   UCSC; uc003cvt.4; human.
DR   CTD; 3615; -.
DR   DisGeNET; 3615; -.
DR   GeneCards; IMPDH2; -.
DR   HGNC; HGNC:6053; IMPDH2.
DR   HPA; CAB020717; -.
DR   HPA; HPA001400; -.
DR   MIM; 146691; gene.
DR   neXtProt; NX_P12268; -.
DR   OpenTargets; ENSG00000178035; -.
DR   PharmGKB; PA29863; -.
DR   eggNOG; KOG2550; Eukaryota.
DR   eggNOG; COG0516; LUCA.
DR   eggNOG; COG0517; LUCA.
DR   GeneTree; ENSGT00530000062923; -.
DR   HOGENOM; HOG000165752; -.
DR   HOVERGEN; HBG052122; -.
DR   KO; K00088; -.
DR   OMA; IHKFIPY; -.
DR   OrthoDB; EOG091G0EAV; -.
DR   PhylomeDB; P12268; -.
DR   TreeFam; TF300378; -.
DR   BioCyc; MetaCyc:HS11242-MONOMER; -.
DR   BRENDA; 1.1.1.205; 2681.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-73817; Purine ribonucleoside monophosphate biosynthesis.
DR   SABIO-RK; P12268; -.
DR   UniPathway; UPA00601; UER00295.
DR   ChiTaRS; IMPDH2; human.
DR   EvolutionaryTrace; P12268; -.
DR   GeneWiki; IMPDH2; -.
DR   GenomeRNAi; 3615; -.
DR   PRO; PR:P12268; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000178035; -.
DR   CleanEx; HS_IMPDH2; -.
DR   ExpressionAtlas; P12268; baseline and differential.
DR   Genevisible; P12268; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005778; C:peroxisomal membrane; IDA:UniProtKB.
DR   GO; GO:0034774; C:secretory granule lumen; TAS:Reactome.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003938; F:IMP dehydrogenase activity; EXP:Reactome.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0000166; F:nucleotide binding; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0071353; P:cellular response to interleukin-4; IEA:Ensembl.
DR   GO; GO:0006177; P:GMP biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0006183; P:GTP biosynthetic process; IBA:GO_Central.
DR   GO; GO:0046651; P:lymphocyte proliferation; IEA:Ensembl.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0051289; P:protein homotetramerization; IEA:Ensembl.
DR   GO; GO:0009168; P:purine ribonucleoside monophosphate biosynthetic process; TAS:Reactome.
DR   GO; GO:0060041; P:retina development in camera-type eye; IEA:Ensembl.
DR   CDD; cd00381; IMPDH; 1.
DR   Gene3D; 3.20.20.70; -; 2.
DR   HAMAP; MF_01964; IMPDH; 1.
DR   InterPro; IPR013785; Aldolase_TIM.
DR   InterPro; IPR000644; CBS_dom.
DR   InterPro; IPR005990; IMP_DH.
DR   InterPro; IPR015875; IMP_DH/GMP_Rdtase_CS.
DR   InterPro; IPR001093; IMP_DH_GMPRt.
DR   Pfam; PF00571; CBS; 2.
DR   Pfam; PF00478; IMPDH; 1.
DR   PIRSF; PIRSF000130; IMPDH; 1.
DR   SMART; SM00116; CBS; 2.
DR   TIGRFAMs; TIGR01302; IMP_dehydrog; 1.
DR   PROSITE; PS51371; CBS; 2.
DR   PROSITE; PS00487; IMP_DH_GMP_RED; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; CBS domain; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; DNA-binding; GMP biosynthesis;
KW   Metal-binding; NAD; Nucleus; Oxidoreductase; Phosphoprotein;
KW   Polymorphism; Potassium; Purine biosynthesis; Reference proteome;
KW   Repeat; RNA-binding.
FT   INIT_MET      1      1       Removed. {ECO:0000255|HAMAP-
FT                                Rule:MF_03156,
FT                                ECO:0000269|PubMed:7903306}.
FT   CHAIN         2    514       Inosine-5'-monophosphate dehydrogenase 2.
FT                                /FTId=PRO_0000093673.
FT   DOMAIN      114    173       CBS 1. {ECO:0000255|HAMAP-Rule:MF_03156}.
FT   DOMAIN      179    237       CBS 2. {ECO:0000255|HAMAP-Rule:MF_03156}.
FT   NP_BIND     274    276       NAD.
FT   NP_BIND     324    326       NAD. {ECO:0000255|HAMAP-Rule:MF_03156}.
FT   REGION      364    366       IMP binding.
FT   REGION      387    388       IMP binding.
FT   REGION      411    415       IMP binding. {ECO:0000255|HAMAP-
FT                                Rule:MF_03156}.
FT   ACT_SITE    331    331       Thioimidate intermediate.
FT                                {ECO:0000255|HAMAP-Rule:MF_03156,
FT                                ECO:0000269|PubMed:10097070}.
FT   ACT_SITE    429    429       Proton acceptor. {ECO:0000255|HAMAP-
FT                                Rule:MF_03156}.
FT   METAL       326    326       Potassium; via carbonyl oxygen.
FT                                {ECO:0000255|HAMAP-Rule:MF_03156,
FT                                ECO:0000269|Ref.22}.
FT   METAL       328    328       Potassium; via carbonyl oxygen.
FT                                {ECO:0000255|HAMAP-Rule:MF_03156,
FT                                ECO:0000269|Ref.22}.
FT   METAL       331    331       Potassium; via carbonyl oxygen.
FT                                {ECO:0000255|HAMAP-Rule:MF_03156,
FT                                ECO:0000269|Ref.22}.
FT   METAL       500    500       Potassium; via carbonyl oxygen; shared
FT                                with tetrameric partner.
FT                                {ECO:0000255|HAMAP-Rule:MF_03156}.
FT   METAL       501    501       Potassium; via carbonyl oxygen; shared
FT                                with tetrameric partner.
FT                                {ECO:0000255|HAMAP-Rule:MF_03156}.
FT   METAL       502    502       Potassium; via carbonyl oxygen; shared
FT                                with tetrameric partner.
FT                                {ECO:0000255|HAMAP-Rule:MF_03156}.
FT   BINDING     329    329       IMP. {ECO:0000255|HAMAP-Rule:MF_03156}.
FT   BINDING     441    441       IMP. {ECO:0000255|HAMAP-Rule:MF_03156}.
FT   MOD_RES     122    122       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     160    160       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     400    400       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:15592455}.
FT   MOD_RES     416    416       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     511    511       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   VARIANT     263    263       L -> F (found in transplant patients;
FT                                functional polymorphism; results in 10-
FT                                fold decrease of enzymatic activity;
FT                                dbSNP:rs121434586).
FT                                {ECO:0000269|PubMed:17496727}.
FT                                /FTId=VAR_070542.
FT   CONFLICT    190    191       AG -> RS (in Ref. 1; AAA36112).
FT                                {ECO:0000305}.
FT   STRAND       17     19       {ECO:0000244|PDB:1B3O}.
FT   HELIX        20     24       {ECO:0000244|PDB:1NF7}.
FT   STRAND       25     27       {ECO:0000244|PDB:1NF7}.
FT   HELIX        32     34       {ECO:0000244|PDB:1NF7}.
FT   STRAND       35     37       {ECO:0000244|PDB:1NF7}.
FT   HELIX        46     48       {ECO:0000244|PDB:1NF7}.
FT   STRAND       53     58       {ECO:0000244|PDB:1NF7}.
FT   STRAND       60     67       {ECO:0000244|PDB:1NF7}.
FT   TURN         71     73       {ECO:0000244|PDB:1NF7}.
FT   HELIX        77     85       {ECO:0000244|PDB:1NF7}.
FT   STRAND       89     91       {ECO:0000244|PDB:1B3O}.
FT   HELIX        97    108       {ECO:0000244|PDB:1NF7}.
FT   TURN        109    113       {ECO:0000244|PDB:1B3O}.
FT   STRAND      123    125       {ECO:0000244|PDB:1B3O}.
FT   STRAND      142    149       {ECO:0000244|PDB:1B3O}.
FT   STRAND      152    158       {ECO:0000244|PDB:1B3O}.
FT   HELIX       161    164       {ECO:0000244|PDB:1NF7}.
FT   TURN        175    177       {ECO:0000244|PDB:1NF7}.
FT   STRAND      183    185       {ECO:0000244|PDB:1NF7}.
FT   HELIX       194    203       {ECO:0000244|PDB:1NF7}.
FT   STRAND      209    212       {ECO:0000244|PDB:1B3O}.
FT   STRAND      214    216       {ECO:0000244|PDB:1NF7}.
FT   STRAND      220    222       {ECO:0000244|PDB:1NF7}.
FT   STRAND      247    250       {ECO:0000244|PDB:1NF7}.
FT   HELIX       256    265       {ECO:0000244|PDB:1NF7}.
FT   STRAND      270    273       {ECO:0000244|PDB:1NF7}.
FT   HELIX       281    293       {ECO:0000244|PDB:1NF7}.
FT   STRAND      295    304       {ECO:0000244|PDB:1NF7}.
FT   HELIX       307    316       {ECO:0000244|PDB:1NF7}.
FT   STRAND      319    323       {ECO:0000244|PDB:1NF7}.
FT   STRAND      328    331       {ECO:0000244|PDB:1NF7}.
FT   HELIX       333    336       {ECO:0000244|PDB:1NF7}.
FT   HELIX       343    354       {ECO:0000244|PDB:1NF7}.
FT   HELIX       355    357       {ECO:0000244|PDB:1NF7}.
FT   STRAND      361    365       {ECO:0000244|PDB:1NF7}.
FT   HELIX       370    378       {ECO:0000244|PDB:1NF7}.
FT   STRAND      382    387       {ECO:0000244|PDB:1NF7}.
FT   HELIX       388    390       {ECO:0000244|PDB:1NF7}.
FT   STRAND      396    398       {ECO:0000244|PDB:1NF7}.
FT   STRAND      404    406       {ECO:0000244|PDB:1NF7}.
FT   STRAND      409    412       {ECO:0000244|PDB:1NF7}.
FT   TURN        417    419       {ECO:0000244|PDB:1NF7}.
FT   STRAND      444    447       {ECO:0000244|PDB:1NF7}.
FT   HELIX       453    471       {ECO:0000244|PDB:1NF7}.
FT   HELIX       476    484       {ECO:0000244|PDB:1NF7}.
FT   STRAND      490    492       {ECO:0000244|PDB:1NF7}.
FT   HELIX       495    501       {ECO:0000244|PDB:1NF7}.
SQ   SEQUENCE   514 AA;  55805 MW;  876BEA0EC1DDBEE9 CRC64;
     MADYLISGGT SYVPDDGLTA QQLFNCGDGL TYNDFLILPG YIDFTADQVD LTSALTKKIT
     LKTPLVSSPM DTVTEAGMAI AMALTGGIGF IHHNCTPEFQ ANEVRKVKKY EQGFITDPVV
     LSPKDRVRDV FEAKARHGFC GIPITDTGRM GSRLVGIISS RDIDFLKEEE HDCFLEEIMT
     KREDLVVAPA GITLKEANEI LQRSKKGKLP IVNEDDELVA IIARTDLKKN RDYPLASKDA
     KKQLLCGAAI GTHEDDKYRL DLLAQAGVDV VVLDSSQGNS IFQINMIKYI KDKYPNLQVI
     GGNVVTAAQA KNLIDAGVDA LRVGMGSGSI CITQEVLACG RPQATAVYKV SEYARRFGVP
     VIADGGIQNV GHIAKALALG ASTVMMGSLL AATTEAPGEY FFSDGIRLKK YRGMGSLDAM
     DKHLSSQNRY FSEADKIKVA QGVSGAVQDK GSIHKFVPYL IAGIQHSCQD IGAKSLTQVR
     AMMYSGELKF EKRTSSAQVE GGVHSLHSYE KRLF
//
